A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin

详细信息    查看全文

• 作者：Isao Ito (1) iisao@med.nagoya-u.ac.jp
  Yasuhiko Ito (12)
  Masashi Mizuno (12)
  Yasuhiro Suzuki (12)
  Kaoru Yasuda (1)
  Takenori Ozaki (1)
  Tomoki Kosugi (1)
  Yoshinari Yasuda (13)
  Waichi Sato (1)
  Naotake Tsuboi (1)
  Shoichi Maruyama (1)
  Enyu Imai (1)
  Seiichi Matsuo (1)
• 关键词：Oxaliplatin – ; Hemolytic anemia – ; Thrombocytopenia – ; Acute kidney injury
• 刊名：Clinical and Experimental Nephrology
• 出版年：2012
• 出版时间：June 2012
• 年：2012
• 卷：16
• 期：3
• 页码：490-494
• 全文大小：237.3 KB
• 参考文献：1. Maindrault-Goebel F, Louvet C, Andr茅 T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer. 1999;35:1338–42.
  2. Twelves C. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology. 2002;16:23–6.
  3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.
  4. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29:11–20.
  5. Lee HH, Hur H, Kim SH, Park AR, Kim W, Jeon HM. Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat. 2010;42:18–23.
  6. Desrame J, Broustet H, de Darodes Tailly P, Girard D, Saissy JM. Oxaliplatin-induced haemolytic anaemia. Lancet. 1999;354:1179–80.
  7. Pinotti G, Martinelli B. A case of acute tubular necrosis due to oxaliplatin. Ann Oncol. 2002;13:1951–2.
  8. Hofheinz RD, Nguyen XD, Buchheidt D, Kerowgan M, Hehlmann R, Hochhaus A. Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemother Pharmacol. 2004;53:276–7.
  9. Labaye J, Sarret D, Duvic C, Herody M, Didelot F, Nedelec G, et al. Renal toxicity of oxaliplatin. Nephrol Dial Transplant. 2005;20:1275–6.
  10. Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol. 2006;6:5.
  11. Buti S, Ricc貌 M, Chiesa MD, Copercini B, Tomasello G, Brighenti M, et al. Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report. Anticancer Drugs. 2007;18:297–300.
  12. Ulusakarya A, Misra S, Haydar M, Habert H, Castagne V, Gumus Y, et al. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol. 2010;27:1425–6.
  13. Chaplin H Jr. Clinical usefulness of specific antiglobulin reagents in autoimmune hemolytic anemias. Prog Hematol. 1973;8:25.
  14. Font茫o-Wendel R, Hoff PM, Lazar A, Freitas D, Novis Y, Patah P, et al. Immune-mediated pancytopenia induced by oxaliplatin: a case report. Transfusion. 2010;50:1453–9.
  15. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;2010:207084.
  16. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141–5.
  17. Chow KM, Lai FM, Wang AY, Chan YL, Tang NL, Li PK. Reversible renal failure in paroxysmal nocturnal hemoglobinuria. Am J Kidney Dis. 2001;37:E17.
  18. Honda N, Hishida A. Pathophysiology of experimental nonoliguric acute renal failure. Kidney Int. 1993;43:513–21.
• 作者单位：1. Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550 Japan2. Department of Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, 466-8550 Japan3. Department of CKD Initiatives, Nagoya University Graduate School of Medicine, Nagoya, 466-8550 Japan
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Nephrology
  Internal Medicine
  Urology and Andrology
  
• 出版者：Springer Japan
• ISSN：1437-7799

文摘

Oxaliplatin is effective in advanced colorectal cancer and is known to have relatively few side effects, such as hemolysis and renal toxicity. We report a case of acute kidney injury (AKI) after treatment with a combination of oxaliplatin, folinic acid and 5-fluorouracil or capecitabine. The patient developed acute renal failure, hemolytic anemia and thrombocytopenia after the 34th course of chemotherapy including oxaliplatin. A positive direct antiglobulin test and detection of immunoglobulin G and complement C3b and C3d on erythrocytes suggested the diagnosis of immune-related severe intravascular hemolytic anemia. She was successfully treated and recovered using plasma exchange, corticosteroids and hemodialysis therapy. Only seven other cases of AKI associated with oxaliplatin use have been reported to date. As in this case, acute hemolysis due to autoimmune mechanisms and subsequent AKI occurred suddenly after frequent use of oxaliplatin in four of those cases. We should be aware that oxaliplatin may cause sudden life-threatening hemolysis by drug-induced antibodies and subsequent AKI, even though oxaliplatin is frequently administered without side effects. This represents the first case report of AKI-related hemolysis due to oxaliplatin in Japan.